Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Biocon Current Valuation Assessment
In accordance with recently published financial statements Biocon Limited has Current Valuation of 65.48 B. This is 127.59% higher than that of Healthcare sector, and 177.17% higher than that of Biotechnology industry, The Current Valuation for all stocks is 54.96% higher than the company.
Filter other Stocks by Current Valuation
Biocon Limited is rated third in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 1.48 Trillion. Biocon holds roughly 65.48 Billion in current valuation claiming about 4% of stocks in Biotechnology industry.
Follow Biocon Current Valuation with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Other Biocon Fundamentals